Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | FASN | P49327 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4920109 | 0.91 | FASN (0.66) | MEN1KMT2APOLBHPGDHDAC4 | |
| SCHEMBL5428425 | 0.90 | MEN1 (0.56) | MEN1KMT2AKDM4EPKMGPR119 | |
| SCHEMBL3900270 | 0.89 | KMT2A (0.70) | MEN1KMT2AGPR119POLBHPGD | |
| SCHEMBL8252454 | 0.87 | KMT2A (0.72) | MEN1KMT2AGPR119POLBHPGD | |
| SCHEMBL15764549 | 0.87 | MEN1 (0.56) | MEN1KMT2AKDM4EPKMGPR119 | |
| SCHEMBL5511049 | 0.86 | MEN1 (0.60) | MEN1KMT2AKDM4EGPR119POLB | |
| SCHEMBL693701 | 0.86 | KDM4E (0.53) | MEN1KMT2AKDM4EPKMGPR119 | |
| SCHEMBL13464773 | 0.86 | KDM4E (0.55) | MEN1KMT2AKDM4EPKMGPR119 | |
| SCHEMBL3960220 | 0.86 | MEN1 (0.66) | MEN1KMT2AGPR119POLBHDAC4 | |
| SCHEMBL5537347 | 0.86 | KMT2A (0.70) | MEN1KMT2AGPR119POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465869-A4 | MODULATORS OF LXR | X CEPTOR THERAPEUTICS INC (US) | 2005-12-28 | — | — | EP | claimed |
| JP-2005536450-A | — | — | 2005-12-02 | — | — | JP | claimed |
| EP-1465869-A1 | MODULATORS OF LXR | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | claimed |
| WO-2003059884-A1 | MODULATORS OF LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| CN-117820287-B | Magnolol derivative, and preparation method and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-120025297-A | Mycobacterium membrane protein MmpL inhibitor, pharmaceutical composition and application thereof | 和径医药科技（上海）有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-117820287-A | Magnolol derivative, and preparation method and application thereof | 中国药科大学 | 2024-04-05 | — | — | CN | disclosed |
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9815853-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2696937-B1 | THIOAMIDE, AMIDOXIME AND AMIDRAZONE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-12-15 | — | — | US | disclosed |
| EP-1465869-A4 | MODULATORS OF LXR | X CEPTOR THERAPEUTICS INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| EP-1492534-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-01-05 | — | — | EP | disclosed |
| EP-1465869-A1 | MODULATORS OF LXR | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004029044-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | EURO-CELTIQUE, S.A. (LU) | 2004-04-08 | — | — | WO | disclosed |
| WO-2003082288-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003059884-A1 | MODULATORS OF LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| US-4247549-A | Piperazine-1-carboxylic acid esters possessing antidepressant or analgesic activity | ICI AMERICAS INC. (US) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | KLKB1, KLK1, KLK2 | MEN1 1461/4885KMT2A 1323/4885KDM4E 927/4885 |
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | MEN1 1461/4885KMT2A 1323/4885KDM4E 927/4885 |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | MEN1 1461/4885KMT2A 1323/4885KDM4E 927/4885 |
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | HDAC1, HDAC7, HDAC11 | MEN1 3571/4885KMT2A 80/4885KDM4E 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.